Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Musc Foundation for Research Development maintains an extensive and highly diversified prosecution pipeline within the Biotechnology & Pharmaceuticals technology area, currently managing 8 pending office actions. This substantial volume of activity reflects a broad and ongoing commitment to intellectual property development in the life sciences. These actions are distributed across 8 distinct examiners, which provides the foundation with a wide array of examiner perspectives and minimizes the influence of any single reviewer on the overall portfolio.
The foundation's prosecution efforts are spread across 7 distinct art units, indicating a vast range of technical specializations within the biotech and pharmaceutical sectors. COUNTS, GARY W is identified as the busiest examiner, although he is responsible for only 1 pending office action. This distribution reveals that the workload is perfectly balanced among the 8 distinct examiners, with each handling a single pending matter. This highly decentralized structure across many art units is ideal for a research foundation, as it allows for independent progress across multiple technical fields.
Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 4 (50%) |
| Double-patenting only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 2 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COUNTS, GARY W | 1 | 58.9% | +29.5% |
| SZNAIDMAN, MARCOS L | 1 | 37.3% | +16.2% |
| EDWARDS, PHILIP CHARLES | 1 | 85.1% | +15.2% |
| PAULUS, ERIN VIRGINIA | 1 | 21.1% | +93.8% |
| NGUYEN, HUONG Q | 1 | 45.7% | +43.9% |
| HIRAKIS, SOPHIA P | 1 | 56.1% | +73.5% |
| BALLARD, KIMBERLY | 1 | 53.7% | +49.0% |
| DEBERRY, REGINA M | 1 | 50.1% | +30.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 78d overdue |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 29d overdue |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 29d overdue |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 10d overdue |
| 17317057 | DETECTION OF AUTOREACTIVE FECAL IMMUNOGLOBULIN A (IGA) FOR DIAGNOSIS OF LUPUS | BALLARD, KIMBERLY | 34d |
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | COUNTS, GARY W | — |
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | — |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | DEBERRY, REGINA M | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 3792 | 1 |
| 1631 | 1 |
| 3791 | 1 |
| 1623 | 1 |
| 1675 | 1 |
| 1647 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18632697 | BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME | COUNTS, GARY W | — | §102§103§112DP | Non-Final OA | — | Pending | Apr 11, 2024 |
| 18478261 | COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL OR MITOCHONDRIAL DISEASES | SZNAIDMAN, MARCOS L | 1628 | §102§103 | Non-Final OA | 10d overdue | Pending | Sep 29, 2023 |
| 18455834 | MOTION-ACTIVATED, CLOSED-LOOP NON-INVASIVE VAGUS NERVE STIMULATION FOR NEUROREHABILITATION | EDWARDS, PHILIP CHARLES | 3792 | §103 | Final Rejection | — | Pending | Aug 25, 2023 |
| 18247519 | Advanced Cell-Permeable Peptide Carriers | PAULUS, ERIN VIRGINIA | 1631 | §103 | Final Rejection | 29d overdue | Pending | Mar 31, 2023 |
| 18191314 | MONITORING NEUROLOGICAL FUNCTIONAL STATUS | NGUYEN, HUONG Q | 3791 | §103 | Non-Final OA | 29d overdue | Pending | Mar 28, 2023 |
| 18155587 | G9A INHIBITION DECREASES STRESS-INDUCED AND DEPENDENCE-INDUCED ESCALATION OF ALCOHOL DRINKING | HIRAKIS, SOPHIA P | 1623 | §102§103§112 | Final Rejection | 78d overdue | Pending | Jan 17, 2023 |
| 17317057 | DETECTION OF AUTOREACTIVE FECAL IMMUNOGLOBULIN A (IGA) FOR DIAGNOSIS OF LUPUS | BALLARD, KIMBERLY | 1675 | §103 | Final Rejection | 34d | Pending | May 11, 2021 |
| 17279857 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF CANCER | DEBERRY, REGINA M | 1647 | DP | Final Rejection | — | Pending | Mar 25, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial